Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

243
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
243
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

379
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
379
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

207
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
207

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plasma Sphingomyelin as a Post-Treatment Monitoring Biomarker for Pathological Response in Locally Advanced Rectal Cancer.

Cancers·2026
Same author

Balloon-assisted retrograde cerebral venography for enhanced visualization of the posterior and lateral dural venous sinuses: a feasibility study.

Neuroradiology·2026
Same author

Morpho-cultural, pathogenic, and molecular diversity, and population structure analysis of <i>Bipolaris sorokiniana</i> causing spot blotch disease in wheat.

Frontiers in microbiology·2026
Same author

Gender discrimination, marital attitude, and perceived choice and awareness as explanatory factors of flourishing among young Indian unmarried women.

Discover mental health·2026
Same author

Global patterns of parasite sharing among freshwater turtles.

Parasitology research·2026
Same author

Preclinical evaluation of <i>Asparagus stipularis</i> in a rat model of metabolic syndrome and development of its nanoencapsulated form.

Drug development and industrial pharmacy·2026

Related Experiment Video

Updated: Sep 16, 2025

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

11.2K

Inhalable N-Acetylcysteine-loaded Lactose-coated PLGA Nanoparticles for Tuberculosis Treatment.

Kabi Raj Chaudhary1, Cláudia Viegas2,3,4,5, Paola Pirela4,5

  • 1Department of Pharmaceutics, ISF College of Pharmacy, Moga, Affiliated to IK Gujral Punjab Technical University, Jalandhar, Punjab, 142001, India.

Pharmaceutical Research
|July 10, 2025
PubMed
Summary

Researchers developed novel lactose-coated N-acetylcysteine (NAC)-loaded Poly(lactic-co-glycolic acid) (PLGA) nanoparticles for inhalation. These nanoparticles show promising antimycobacterial activity against Mycobacterium Tuberculosis, offering a potential new treatment for tuberculosis (TB).

Keywords:
N-acetylcysteinePLGA nanoparticlesdry powderinhalable particlespulmonary deliverytuberculosis

More Related Videos

PLGA Nanoparticles Formed by Single- or Double-emulsion with Vitamin E-TPGS
12:48

PLGA Nanoparticles Formed by Single- or Double-emulsion with Vitamin E-TPGS

Published on: December 27, 2013

65.6K
Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
04:22

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals

Published on: March 30, 2017

7.8K

Related Experiment Videos

Last Updated: Sep 16, 2025

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

11.2K
PLGA Nanoparticles Formed by Single- or Double-emulsion with Vitamin E-TPGS
12:48

PLGA Nanoparticles Formed by Single- or Double-emulsion with Vitamin E-TPGS

Published on: December 27, 2013

65.6K
Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
04:22

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals

Published on: March 30, 2017

7.8K

Area of Science:

  • Nanotechnology
  • Pharmaceutical Sciences
  • Infectious Diseases

Background:

  • N-acetylcysteine (NAC) possesses mucolytic, antioxidant, and potential antimycobacterial properties.
  • Glutathione (GSH) is clinically used for various conditions, including tuberculosis (TB).
  • NAC's direct antimycobacterial effects and ability to enhance GSH levels present therapeutic potential for TB.

Purpose of the Study:

  • To develop an effective inhalable drug delivery system for NAC.
  • To create lactose-coated NAC-loaded Poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NAC-PLGA NPs).

Main Methods:

  • NAC-PLGA NPs were synthesized using a double emulsion method.
  • Lactose was utilized as a cryoprotectant and dispersant for inhalable formulations.
  • Physicochemical properties (size, PdI, ZP, morphology), in vitro release, and lung deposition were evaluated.

Main Results:

  • Lactose-coated NAC-PLGA NPs exhibited favorable physicochemical characteristics: particle size of 310 nm, PdI of 0.15, and ZP of -11.5 mV.
  • In vitro studies demonstrated a biphasic release profile and desirable lung deposition parameters.
  • Superior in vitro antimycobacterial activity against Mycobacterium Tuberculosis (MTB) H37Rv was observed.

Conclusions:

  • Lactose-coated NAC-PLGA NPs represent a promising inhalable formulation for TB treatment.
  • This novel nanoparticle system may offer new therapeutic avenues for drug-refractory and drug-resistant TB.
  • Further development could lead to advanced treatment options for tuberculosis.